Mitigation of experimental inflammatory bowel disease in guinea pigs by selective elimination of the aerobic gram-negative intestinal microflora.
D000818:Animals; D001419:Bacteria / Q000145:classification; D001835:Body Weight; D002351:Carrageenan / Q000009:adverse effects; D002432:Cecum / Q000473:pathology; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D003106:Colon / Q000473:pathology; D004195:Disease Models, Animal; D004755:Enterobacteriaceae / Q000302:isolation & purification; D005243:Feces / Q000382:microbiology; D006168:Guinea Pigs; D007413:Intestinal Mucosa / Q000473:pathology; D008297:Male; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D014456:Ulcer / Q000473:pathology
D002351:Carrageenan; D014295:Trimethoprim; D013420:Sulfamethoxazole